AstraZeneca PLC
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Strensiq (asfotase alfa) — Worldwide YoY CER by Quarter
Strensiq (asfotase alfa) — Worldwide YoY CER (%) (%)
AstraZeneca Strensiq (asfotase alfa) — Worldwide YoY CER: 36.0% in Q2 2026, up 21.0 pts from a year earlier.
Latest, Q2 2026
36.0%
Period ended Jun 30, 2026
Change on a year earlier
+21.0 pts
15.0% in Q2 2025
History
20 quarters
Since Q3 2021
Sources
20
Documents cited below
Where the Q2 2026 figure comes from
“|| Strensiq | | 536 | | 36 | | 36 | | 452 | | 42 | | 16 | | 2 | | 2 | | 37 | | 20 | | 14 | | 31 | | 7 | | 15”
Source: Form 6-K FY2026Q2 Earnings Release ↗
Reported in Form 6-K / 20-F Product Sales Table.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). AstraZeneca Strensiq (asfotase alfa) — Worldwide YoY CER (%), quarterly Q3 2021–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-strensiq-world-cer-yoy
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.